Overview
Vogt-Koyanagi-Harada disease (often called VKH disease) is a rare condition in which the body's immune system mistakenly attacks cells that contain melanin, a pigment found in the eyes, skin, inner ear, and the membranes surrounding the brain. It is not inherited in a simple genetic pattern but is considered an autoimmune disorder that occurs in people with certain genetic predispositions, particularly specific HLA (human leukocyte antigen) types. The disease typically progresses through several stages. It often begins with headaches, neck stiffness, fever, and flu-like symptoms. Within days, patients develop serious eye inflammation, including blurred vision, eye pain, sensitivity to light, and sometimes detachment of the retina. If untreated, VKH can lead to permanent vision loss. Later stages may involve whitening of the hair (poliosis), loss of skin color in patches (vitiligo), and hearing problems such as ringing in the ears or hearing loss. Treatment focuses on suppressing the immune system to control inflammation. High-dose corticosteroids are the first-line therapy, often followed by steroid-sparing immunosuppressive medications for long-term management. Early and aggressive treatment is critical to preserving vision and preventing recurrences. With proper treatment, many patients can maintain useful vision, though chronic or recurrent inflammation may lead to complications like glaucoma, cataracts, or ongoing vision problems.
Also known as:
Key symptoms:
Blurred or decreased visionEye pain and rednessSensitivity to lightFloaters in visionHeadachesNeck stiffnessRinging in the ears (tinnitus)Hearing lossWhitening or graying of hair and eyelashesPatches of skin losing color (vitiligo)Fever and flu-like symptoms early onNauseaPain with eye movementSwelling of the optic discHair loss (alopecia)
Clinical phenotype terms (37)— hover any for plain English
Multifactorial
Caused by a mix of several genes and environmental factors
Adult
Begins in adulthood (age 18 or older)
FDA & Trial Timeline
1 eventTianjin Medical University
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
No FDA-approved treatments are currently listed for Vogt-Koyanagi-Harada disease.
1 clinical trialare actively recruiting — trials can provide access to cutting-edge therapies.
View clinical trials →Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Vogt-Koyanagi-Harada disease.
Community
No community posts yet. Be the first to share your experience with Vogt-Koyanagi-Harada disease.
Start the conversation →Latest news about Vogt-Koyanagi-Harada disease
No recent news articles for Vogt-Koyanagi-Harada disease.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.What stage is my VKH disease, and how much damage has already occurred in my eyes?,How long will I need to take immunosuppressive medications, and what are the risks?,What signs should I watch for that would indicate a disease flare?,Are there newer or biologic treatments that might be appropriate for me?,How often will I need eye exams and blood tests to monitor my condition?,What is my long-term outlook for preserving my vision?,Should I see other specialists such as a dermatologist or audiologist for my other symptoms?
Common questions about Vogt-Koyanagi-Harada disease
What is Vogt-Koyanagi-Harada disease?
Vogt-Koyanagi-Harada disease (often called VKH disease) is a rare condition in which the body's immune system mistakenly attacks cells that contain melanin, a pigment found in the eyes, skin, inner ear, and the membranes surrounding the brain. It is not inherited in a simple genetic pattern but is considered an autoimmune disorder that occurs in people with certain genetic predispositions, particularly specific HLA (human leukocyte antigen) types. The disease typically progresses through several stages. It often begins with headaches, neck stiffness, fever, and flu-like symptoms. Within days,
How is Vogt-Koyanagi-Harada disease inherited?
Vogt-Koyanagi-Harada disease follows a multifactorial inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Vogt-Koyanagi-Harada disease typically begin?
Typical onset of Vogt-Koyanagi-Harada disease is adult. Age of onset can vary across affected individuals.
Are there clinical trials for Vogt-Koyanagi-Harada disease?
Yes — 1 recruiting clinical trial is currently listed for Vogt-Koyanagi-Harada disease on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Which specialists treat Vogt-Koyanagi-Harada disease?
5 specialists and care centers treating Vogt-Koyanagi-Harada disease are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.